Den mest almindelige bivirkning, der blev rapporteret med en højere incidens hos patienter i aprepitantbehandling end hos patienter i standardbehandling med moderat emetogen kemoterapi, var træthed (2, 5%).
The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving moderately emetogenic chemotherapy was fatigue (2.5%).